Booster Therapeutics has announced its inception to develop a new class of proteasome activator medicines for ...

KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated ...

At CPHI Europe, Angela Vollstedt, global director of Cell & Gene Therapies at Novartis discussed scale up strategies for cell ...

High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.

Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, ...

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and ...

At CPHI Europe, an expert discussed the promise of gummies as a drug delivery system and their unique manufacturing ...

According to Lancet Public Health, the incidence of probable food allergy more than doubled in England between 2008 and 2018.

Eli Lilly and insitro said the deals offers a “new paradigm” for collaborations between major pharmaceutical companies and ...

Biogen plans to start a Phase III trial for felzartamab as a treatment for antibody-mediated rejection, and two other ...

As a risk factor for future serious health conditions, the early prevention, detection and management of type 2 diabetes are ...

Boehringer Ingelheim and Circle Pharma have signed a partnership and licence agreement focused on developing a new cancer ...